Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression during or following platinum‐containing chemotherapy. A Cochrane Rapid Review
Referencias
Additional references
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J‐L, Fong L, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. The New England Journal of Medicine2017; Vol. 376, issue 11:1015‐26.
Veritas Health Innovation. Covidence. Version accessed 28 August 2017. Melbourne, Australia: Veritas Health Innovation, 2017.
Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006;107(3):506‐13.
Witjes JA, Compérat E, Cowan NC, Gakis G, Hernández V, Lebret T, et al. EAU guidelines on muscle‐invasive and metastatic bladder cancer. European Association of Urology 2017;Available from: http://uroweb.org/guideline/bladder‐cancer‐muscle‐invasive‐and‐metastatic/, accessed,on 14/10/2017.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer2009; Vol. 45, issue 2:228‐47.
Thomson Reuters. EndNote X5. Version X5. Thomson Reuters, 2011.
Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, et al. Assessment of tumoral PD‐L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology 2015;85(3):703.e1‐6.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet].. Lyon, France: International Agency for Research on Cancer 2013;Available from: http://globocan.iarc.fr, accessed on 07/10/2017.
McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 1 February 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
Gupta S, O'Donnell P, Plimack ER, Berger R, Montgomery B, Heath K, et al. Mp68‐11 a Phase 1B Study of Pembrolizumab (Pembro; Mk‐3475) for Advanced Urothelial Cancer. The Journal of Urology 2015;193(4):e861‐2.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck‐Ytter Y, Schünemann HJ, et al. GRADE: what is "quality of evidence" and why is it important to clinicians?. BMJ (Clinical Research Ed.) 2008;336(7651):995‐8.
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383‐94.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analysis. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. Canadian Medical Association Journal 2013;185(4):E201‐11.
Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD‐L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD‐L1 blockade. Proceedings of the National Academy of Sciences of the United States of America 2002;99(19):12293‐7.
Kim JW, Bellmunt J, Powles T, Loriot Y, Vogelzang MJ, Zambrano CC, et al. Clinical activity, safety, and biomarkers of MPDL3280A in metastatic urothelial bladder cancer: Additional analysis from phase IA study. Journal of Clinical Oncology 2015;33(7_suppl):297‐297.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]
Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. Journal of Clinical Oncology 1990;8(6):1050‐5.
Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette‐Guerin in the treatment of superficial bladder tumors. The Journal of Urology 1976;116(2):180‐3.
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 2017;15(10):1240‐1267.
Park JC, Hahn NM. Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies. Urologic Oncology: Seminars and Original Investigations 2016;34(12):566‐76.
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. [PUBMED: 9921604]
Plimack ER, Bellmunt J, Gupta S, Berger R, Chow LQ, Juco J. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE‐012): a non‐randomised, open‐label, phase 1b study. Lancet Oncology 2017;18(2):212‐220.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ribas A. Releasing the brakes on cancer immunotherapy. The New England Journal of Medicine 2015;373(16):1490–1492.
Rosenberg JE, Hoffman‐Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum‐based chemotherapy: a single‐arm, multicentre, phase 2 trial. The Lancet 2016;387(10031):1909‐20.
Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). [S3‐Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 1.1]. AWMF‐Registrierungsnummer 032/038OL 2016;Available from http://leitlinienprogramm‐onkologie.de/Harnblasenkarzinom.92.0.html, accessed on 14/10/2017.
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015;348(6230):56‐61.
Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open‐label, two‐stage, multi‐arm, phase 1/2 trial. The Lancet Oncology 2016;17(11):1590‐8.
Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta‐analyses of randomised controlled trials. BMJ (Clinical Research Ed.) 2011;343:d4002. [DOI: 10.1136/bmj.d4002]
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. [PUBMED: 17555582]
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of Clinical Oncology 2000;18(17):3068‐77.
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601‐5. [DOI: 10.1136/bmj.39465.451748.AD]
